Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model

American Journal of Therapeutics

Volumn 12, Issue 5, 2005, Pages 385-397

  Rohatagi, Shashank ^a   Krishnaswami, Sriram ^a   Pfister, Marc ^a   Sahasranaman, Srikumar ^a  

^a SANOFI   (France)

Author keywords

Asthma therapy; Ciclesonide; Corticosteroids; Cortisol

Indexed keywords

CICLESONIDE; CORTICOSTEROID; DESISOBUTYRYL-CICLESONIDE; HYDROCORTISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMATIC STATE; BODY WEIGHT; CHILD; CIRCADIAN RHYTHM; COMPARTMENT MODEL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG STRUCTURE; FEMALE; HUMAN; HYDROCORTISONE RELEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGE FACTORS; AGED; ASTHMA; BODY WEIGHT; CHILD; CIRCADIAN RHYTHM; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; LUNG; MIDDLE AGED; MODELS, BIOLOGICAL; PREGNENEDIONES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 26844558866     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000155110.69831.75     Document Type: Article

References (32)

1. Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J. 2001;17: 1083-1088.
2. Engelstatter R, Langdon C, Bethke T, et al. Efficacy of ciclesonide after twelve-week treatment of bronchial asthma. Am J Respir Crit Care Med. 2002;165:A766.
3. O'Connor B, Sips P, Engelstatter R, et al. Management of moderate to severe bronchial asthma by ciclesonide: a 12-week trial. Am J Respir Crit Care Med. 2002;165:A767.
4. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy. 2005;60:330-337.
5. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine in asthmatic patients. Pulm Pharmacol Ther. In press.
6. Ciclesonide BY. 9010, ciclesonide-DPI, ciclesonide-MDI, EL 876. Drugs R D. 2002;3:407-410.
7. Dent G. Ciclesonide. Curr Opin Investig Drugs. 2002;3: 78-83.
8. Kanniess F, Richter K, Bohme S, et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther. 2001; 14:141-147.
9. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab. 2002;87:2160-2163.
10. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med. 1997;91(suppl A):22-28.
11. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S440-S446.
12. Nave R, Zech K, Bethke TD. Oropharyngeal deposition of inhaled ciclesonide and budesonide in healthy subjects. J Allergy Clin Immunol. 2003;111:A606.
13. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45:146-152.
14. Moellman H, et al. Pharmacokinetic-pharmacodynamic correlations of corticosteroids. In: Derendorf H, Hochhaus G, eds. Handbook of Pharmacokinetic/Pharmacodynamic Correlation. Handbooks in Pharmacology and Toxicology. Vol. 19. Boca Raton, FL: CRC Press; 1995: 323-353.
15. Lipworth BJ, Wilson B. Dose response to inhaled corticosteroids. Semin Respir Crit Care Med. 1998;19:625-646.
16. Jusko WJ, Ludwig EA. Corticosteroids. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vol. 27. Applied Therapeutics. Spokane, WA: 1992:1-27.
17. Koopmans RP, Braat MC, Oosterhuis B, et al. Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model J Pharmacol Exp Ther. 1992;262: 503-508.
18. Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol. 2003;43:365-378.
19. Rohatagi S, Derendorf H, Zech K, et al. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide. J Allergy Clin Immunol. 2003;111:A598.
20. Kaliner M, Rohatagi S, Zech K, et al. The receptor binding of ciclesonide: comparison to other inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;90:129-130.
21. Nave R, Bethke TD, van Marle SP, et al. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet. 2004;43: 479-486.
22. Boeckmann AJ, Sheiner LB, Beal SB. NONMEM Users Guide. Part IV: NM-TRAN Guide (1992), Part V: Introductory Guide (1994), Part VI: PREDPP Guide (1992). San Francisco: NONMEM Project Group.
23. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. Philadelphia: Lea and Febiger; 1995.
24. Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm. 1990;18:161-173.
25. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 1997;33:313-327.
26. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30:329-332.
27. Aventis Study Report. BY 9010/FHP018: M. Hartmann. Influence of liver cirrhosis on the pharmacokinetics of the active metabolite B9207-201 of ciclesonide in comparison to a control group of healthy subjects. 1998 (210/2000).
28. Rohatagi S, Bye A, Mackie AE, et al. Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur J Pharm Sci. 1996;4:341-350.
29. Chakraborty A, Krzyzanski W, Jusko WJ. Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm. 1999;27:23-43.
30. Derendorf H, Mollmann H, Barth J, et al. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol. 1991;31:473-476.
31. Lipworth BJ, Kaliner MA, LaForce CF, et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol. In Press.
32. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect HPA-axis function in patients with moderate-to-severe persistent asthma. Chest. In Press.